effect overlay
activetrials
Multiple Sclerosis

B-cell repopulation in patients with multiple sclerosis treated with anti-CD20 therapies
 

HREC: 2023.079
Principal Investigator: Prof Tomas Kalincik
Coordinator contact:
Funding: Non-Commercial
Multiple Sclerosis

Prevalence and incidence study of neuromyelitis optica in Australia and New Zealand with population based sensitivity and specificity of NMO IgG antibody positivity
 

HREC: 2010.278
Principal Investigator: Dr Mark Marriott
Coordinator contact:
Funding: Non-Commercial
Multiple Sclerosis

Biomarkers of motor performance in multiple sclerosis: 7T MRI study
 

HREC: 2015.144
Principal Investigator: Prof Trevor Kilpatrick
Coordinator contact: Dr Vivien Li
Funding: Non-Commercial
Multiple Sclerosis

A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profile of LEMTRADA® (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis
 

HREC: 2015.153
Principal Investigator: Dr Mark Marriott
Coordinator contact: Lisa Taylor
Funding: Commercial
Multiple Sclerosis

Prospective clinic and home-based serial monitoring of cognition in relapsing- remitting multiple sclerosis
 

HREC: 2015.174
Principal Investigator: Prof Tomas Kalincik
Coordinator contact: Dr Anneke van der Walt
Funding: Non-Commercial